|
1
|
Ristagno G, Fumagalli F, Bottazzi B,
Mantovani A, Olivari D, Novelli D and Latini R: Pentraxin 3 in
cardiovascular disease. Front Immunol. 10(823)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Balhara J, Koussih L, Zhang J and Gounni
AS: Pentraxin 3: An immuno-regulator in the lungs. Front Immunol.
4(127)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jaillon S, Bonavita E, Gentile S, Rubino
M, Laface I, Garlanda C and Mantovani A: The long pentraxin PTX3 as
a key component of humoral innate immunity and a candidate
diagnostic for inflammatory diseases. Int Arch Allergy Immunol.
165:165–178. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zanetti M, Bosutti A, Ferreira C, Vinci P,
Biolo G, Fonda M, Valente M, Cattin L, Guarnieri G and Barazzoni R:
Circulating pentraxin 3 levels are higher in metabolic syndrome
with subclinical atherosclerosis: Evidence for association with
atherogenic lipid profile. Clin Exp Med. 9:243–248. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lee R, Ahn HR, Shin MH, Kim HN, Lee YH,
Choi SW and Kweon SS: Association of plasma pentraxin-3 level with
lipid levels and cardiovascular risk factors in people with no
history of lipid-lowering medication: The Dong-gu Study. J
Atheroscler Thromb. 26:738–745. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bonacina F, Moregola A, Porte R, Baragetti
A, Bonavita E, Salatin A, Grigore L, Pellegatta F, Molgora M,
Sironi M, et al: Pentraxin 3 deficiency protects from the metabolic
inflammation associated to diet-induced obesity. Cardiovasc Res.
115:1861–1872. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Santilli F, Guagnano MT, Innocenti P,
Aceto L, Vazzana N, Lattanzio S, Liani R, Tripaldi R, Creato V,
Romano M, et al: Pentraxin 3 and platelet activation in obese
patients after gastric banding. Circ J. 80:502–511. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Barazzoni R, Palmisano S, Gortan
Cappellari G, Giuricin M, Moretti E, Vinci P, Semolic A, Guarnieri
G, Zanetti M and Manzini N: Gastric bypass-induced weight loss
alters obesity-associated patterns of plasma pentraxin-3 and
systemic inflammatory markers. Surg Obes Relat Dis. 12:23–32.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ogawa T, Kawano Y, Imamura T, Kawakita K,
Sagara M, Matsuo T, Kakitsubata Y, Ishikawa T, Kitamura K,
Hatakeyama K, et al: Reciprocal contribution of pentraxin 3 and
C-reactive protein to obesity and metabolic syndrome. Obesity
(Silver Spring). 18:1871–1874. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Osorio-Conles O, Guitart M, Chacón MR,
Maymo-Masip E, Moreno-Navarrete JM, Montori-Grau M, Näf S,
Fernandez-Real JM, Vendrell J and Gómez-Foix AM: Plasma PTX3
protein levels inversely correlate with insulin secretion and
obesity, whereas visceral adipose tissue PTX3 gene expression is
increased in obesity. Am J Physiol Endocrinol Metab.
301:E1254–E1261. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Witasp A, Carrero JJ, Michaëlsson K,
Ahlström H, Kullberg J, Adamsson V, Risérus U, Larsson A,
Helmersson-Karlqvist J, Lind L, et al: Inflammatory biomarker
pentraxin 3 (PTX3) in relation to obesity, body fat depots and
weight loss. Obesity (Silver Spring). 22:1373–1379. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Norata GD, Marchesi P, Pulakazhi Venu VK,
Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C,
Mantovani A and Catapano AL: Deficiency of the long pentraxin PTX3
promotes vascular inflammation and atherosclerosis. Circulation.
120:699–708. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Salio M, Chimenti S, De Angelis N, Molla
F, Maina V, Nebuloni M, Pasqualini F, Latini R, Garlanda C and
Mantovani A: Cardioprotective function of the long pentraxin PTX3
in acute myocardial infarction. Circulation. 117:1055–1064.
2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nauta AJ, Bottazzi B, Mantovani A,
Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco
F, Egido J, et al: Biochemical and functional characterization of
the interaction between pentraxin 3 and C1q. Eur J Immunol.
33:465–473. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Erreni M, Manfredi AA, Garlanda C,
Mantovani A and Rovere-Querini P: The long pentraxin PTX3: A
prototypical sensor of tissue injury and a regulator of
homeostasis. Immunol Rev. 280:112–125. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Norata GD, Marchesi P, Pirillo A, Uboldi
P, Chiesa G, Maina V, Garlanda C, Mantovani A and Catapano AL: Long
pentraxin 3, a key component of innate immunity, is modulated by
high-density lipoproteins in endothelial cells. Arterioscler Thromb
Vasc Biol. 28:925–931. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Garlanda C, Bottazzi B, Moalli F, Deban L,
Molla F, Latini R and Mantovani A: Pentraxins and atherosclerosis:
The role of PTX3. Curr Pharm Des. 17:38–46. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yamasaki K, Kurimura M, Kasai T, Sagara M,
Kodama T and Inoue K: Determination of physiological plasma
pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab
Med. 47:471–477. 2009.PubMed/NCBI View Article : Google Scholar
|
